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Abstract 26 
Background 27 
Most smoking cessation guidelines advise quitting abruptly. However, many quit attempts 28 
involve gradual cessation. If gradual is as successful, smokers can be advised to quit either 29 
way. 30 
 31 
Objectives 32 
To examine the success of quitting smoking by reducing first relative to quitting abruptly. 33 
 34 
Design 35 
Randomised controlled non-inferiority trial.  36 
 37 
Setting 38 
Primary care clinics in England. 39 
 40 
Participants 41 
697 adult smokers addicted to tobacco.  42 
 43 
Interventions 44 
Participants quit abruptly or reduced smoking by 75% in the two weeks before quitting. Both 45 
arms received behavioural support from nurses and used nicotine replacement before and 46 
after quit day. 47 
 48 
Outcome measures 49 
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The primary outcome measure was prolonged validated smoking abstinence 4 weeks after 50 
quit day. The secondary outcome was prolonged validated 6-month abstinence. 51 
 52 
Results 53 
At 4 weeks, 39.2% (95%CI: 34.0, 44.4) of the participants in the gradual arm were abstinent 54 
compared with 49.0% (95%CI: 43.8, 54.2) in the abrupt arm (relative risk (RR) 0.80; 95%CI, 55 
0.66, 0.93). At six months, 15.5% (95% CI: 12.0, 19.7) of the participants in the gradual arm 56 
were abstinent compared with 22.0% (95% CI: 18.0, 26.6) in the abrupt arm (RR 0.71; 57 
95%CI, 0.46, 0.91). At four weeks, 34.6% of participants who preferred to quit gradually and 58 
were allocated to quit that way were abstinent compared with 42.0% who were allocated to 59 
quit abruptly, against their preference. 60 
 61 
Limitations 62 
Blinding was impossible. Most participants were white. 63 
 64 
Conclusions  65 
Quitting smoking abruptly is more likely to lead to lasting abstinence than cutting down first, 66 
even for smokers who initially prefer to quit by reduction. 67 
 68 
Trial Registration 69 
Registered on the International Standard Randomised Controlled Trial Number Register 70 
before the start of participant enrolment (ISRCTN22526020). Online at: http://controlled-71 
trials.com/ISRCTN22526020. 72 
 73 
Primary funding source 74 
 4 
 
British Heart Foundation 75 
 76 
 77 
 78 
Word count: 3501  79 
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Introduction 80 
Conventionally smokers are advised to quit abruptly by setting a quit day and stopping 81 
smoking in one step. Worldwide, guidelines for smoking cessation generally recommend 82 
stopping smoking abruptly and do not support reducing cigarettes smoked first (2-4);  83 
however, many smokers report stopping gradually (5-7). It is important to know whether 84 
smokers should be advised against gradual cessation because it might produce lower success 85 
rates.   86 
 87 
Evidence on whether gradual cessation is less effective than abrupt cessation is conflicting. 88 
Observational data on quit attempts made mainly without behavioural support suggest that 89 
stopping abruptly is superior (5, 8). However, a Cochrane review of ten randomised trials 90 
suggests there may be little difference in quit rates achieved using the two approaches (9), 91 
with a relative risk (RR) of 0.94 (95% confidence intervals (CI): 0.79 to 1.13). Several trials 92 
included in the review had design features that make it uncertain that differences in quit rates 93 
were solely due to the method used to achieve abstinence. None were designed to assess non-94 
inferiority, and the pooled 95%CI obtained encompasses a substantial reduction in the 95 
efficacy of quitting gradually compared with quitting abruptly. We conducted a large trial to 96 
test whether an initial gradual reduction in smoking produces non-inferior quit rates to abrupt 97 
cessation. 98 
 99 
Methods 100 
Design 101 
We randomized adult smokers to either gradually reduce their tobacco use over two weeks 102 
prior to a planned quit day, or to stop smoking abruptly on a planned quit day. The gradual 103 
cessation group received short acting nicotine replacement therapy (NRT) and nicotine 104 
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patches prior to the quit day. The abrupt cessation group received only nicotine patches prior 105 
to the quit day.  Both groups received behavioural counseling, as well as nicotine patches and 106 
short acting NRT following the quit day.  Our primary outcome was validated abstinence at 4 107 
weeks following the quit day. We also evaluated 6 month abstinence and whether outcomes 108 
differed according to participants’ preferred method of quitting. 109 
 110 
Participants 111 
We recruited adult smokers addicted to tobacco, defined as those smoking at least 15 112 
cigarettes/12.5 grams of loose tobacco daily and/or having end-expiratory carbon monoxide 113 
(CO) concentration of at least 15 parts per million (ppm). Participants had to be willing to 114 
quit smoking two weeks after trial enrolment. Exclusion criteria were: currently undergoing 115 
cessation treatment; cautions for the use of NRT; participation in other medicinal trials; 116 
circumstances that would mean the demands of trial participation would not be met. People 117 
with dependence upon alcohol or illicit drugs and severe acute or chronic medical or 118 
psychiatric conditions were included unless their conditions were so incapacitating that 119 
meeting the demands of the trial was very unlikely. 120 
 121 
The lead general practitioner at 31 volunteer practices in England searched their electronic 122 
patient records and wrote to all registered patients who smoked to invite them into the study.  123 
Potential participants were encouraged to telephone the researchers, who explained the trial 124 
and screened patients for eligibility. Eligible smokers were booked for an appointment with a 125 
research nurse, where the study was explained, eligibility confirmed, and written informed 126 
consent obtained.  127 
 128 
Interventions 129 
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Participants were asked to set a quit day two weeks after enrolment and the intervention 130 
differed between arms only during these two pre-quit weeks.  In the gradual quit arm, 131 
participants aimed to reduce smoking to half of baseline by the end of the first week (visit -1), 132 
and to a quarter of baseline at the end of the second week (visit 0), in daily increments.  133 
Reduction over two weeks was chosen because there is qualitative evidence that this keeps 134 
people more focused on quitting than longer reduction (10); a trial (11) suggests that it is 135 
more effective than longer reduction; and because the two week preparation for quit day is 136 
current practice (12). Participants in the gradual reduction arm chose one of three structured 137 
reduction programmes: scheduled, hierarchical, or smoke-free periods reduction.  In 138 
scheduled reduction, participants used a timer (usually a mobile phone) to schedule inter-139 
cigarette intervals and smoked only when the timer sounded or for five minutes thereafter. 140 
The time between cigarettes lengthened daily (1, 2). In hierarchical reduction, participants 141 
rated cigarettes from most to least favourite and progressively eliminated either their 142 
favourite or least favoured cigarettes.  In smoke-free periods, participants mapped their 143 
regular day and noted the 30 minute periods within which they smoked. They then 144 
progressively eliminated half, and then three quarters of these. 145 
 146 
In all cases, the nurse drew up reduction schedules with the participant to boost 147 
understanding and memory, and discussed strategies to prompt adherence to the schedules.  148 
Smoking reduction is more successful when participants use NRT (13) so we provided 149 
21mg/24 hour nicotine patches and a choice of short-acting NRT products (gum, lozenge, 150 
nasal spray, sub-lingual tablet, inhalator, mouth spray) during the reduction period. For 151 
products such as gum and lozenge the instruction was to use one dose per cigarette missed. 152 
The short-acting NRT in the gradual arm was used to try to equalise blood nicotine 153 
concentrations in each trial arm prior to quitting. 154 
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 155 
Between baseline appointment and quit date, participants in the abrupt cessation arm were 156 
asked to smoke as normal and not reduce. To balance the behavioural support time, 157 
participants identified the cigarettes they would find hardest to give up and planned strategies 158 
to avoid relapse after quit day.  Prior to quitting, participants in the abrupt arm were asked to 159 
use 21mg/24 hour nicotine patches but no short-acting NRT. NRT was used in this arm prior 160 
to quit day because there is some evidence that pre-cessation NRT increases quit rates and 161 
this balanced this effect between arms (14). 162 
 163 
Other than these differences, the treatment programme in both arms was identical.  164 
Participants were seen by a research nurse at their primary care practice weekly for two 165 
weeks prior to their quit day (baseline visit, visit -1), the day before their quit day (visit 0), 166 
thereafter weekly for four weeks after quitting (visits +1, +2, +3 and +4), and finally eight 167 
weeks after quit day (visit +8). The behavioural support from visit 0 onwards was withdrawal 168 
oriented therapy, typical of a UK smoking cessation clinic (12,15), and the same in both trial 169 
arms. Withdrawal-oriented therapy focuses on the commitment to abstain completely and 170 
provides support early, when withdrawal symptoms are at their worst and relapse most likely. 171 
Pharmacotherapy was identical in both arms from quit day onwards, consisting of a 21mg/24 172 
hour nicotine patch plus a short-acting form of NRT of the participant’s choice.  Participants 173 
were encouraged to use the short-acting form liberally, in anticipation of or in response to 174 
cravings.  175 
 176 
Randomisation 177 
Participants were randomised 1:1 to gradual or abrupt cessation at the baseline visit.  An 178 
independent statistician used Stata to accomplish randomisation stratified by research nurse, 179 
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with randomly ordered blocks of 2, 4, and 6 to ensure balance. After consent, the research 180 
nurse opened sealed numbered envelopes in turn. Where participants quit in pairs (e.g. 181 
husband and wife), one was allocated randomly and the other allocated to the same arm.   182 
 183 
Sample size 184 
Our chosen non-inferiority margin was equivalent to a relative risk (RR) of 0.81 or a 19% 185 
reduction in effectiveness of quitting gradually compared with abruptly.  This is an absolute 186 
difference in quit rates of 9.5% at four weeks assuming 50% quit in the abrupt arm (16). 187 
Using a one-sided alpha of 5%, 343 participants per arm were needed to have 80% power to 188 
detect this difference in the primary outcome.  189 
 190 
Measures 191 
Participant demographics, smoking history, nicotine dependence and preference for gradual 192 
or abrupt quitting were recorded at baseline. At each subsequent clinic session we assessed 193 
amount smoked, salivary cotinine, and measured exhaled carbon monoxide. Tobacco 194 
withdrawal symptoms were also measured using the Mood and Physical Symptoms Scale 195 
(MPSS), and are presented here as the mean score for urges and the mean score for 196 
withdrawal symptoms (17). We also assessed the occurrence of adverse events and 197 
participants rated the severity of possible symptoms of nicotine overdose during the two 198 
weeks using NRT and smoking. Nicotine overdose symptoms were provided as a checklist 199 
and participants were asked: ‘Have you been troubled by any of the following problems in 200 
the past 24 hours?’ They rated each symptom on a scale ranging from ‘Not at all’ to 201 
‘Extremely’. All participants were asked to complete daily diaries in the two weeks prior to 202 
quit day to measure adherence to medication and behavioural instructions.  Trial arm 203 
preference was re-assessed at four week follow-up.  204 
 10 
 
 205 
The primary outcome was Russell Standard four-week abstinence. The Russell Standard 206 
allows a two week grace period from quit day for slips and uses an intention to treat 207 
approach, assuming people lost to follow-up are smokers. Russell Standard abstinence is 208 
validated by an exhaled carbon monoxide concentration of <10ppm (18). Secondary 209 
outcomes were Russell Standard abstinence at eight week and six month follow-up; seven-210 
day point prevalence abstinence at four week, eight week and six month follow-ups, validated 211 
by exhaled carbon monoxide of <10ppm; and urges to smoke and nicotine withdrawal 212 
symptoms at one and four weeks follow-up.  213 
 214 
Data analysis 215 
In the analysis of abstinence, we present relative risks due to the high incidence of abstinence 216 
(>10%). The primary non-inferiority analysis (abstinence at 4 weeks) was based on a one-sided 217 
alpha of 0.05 and therefore a 90% confidence interval was calculated. In accordance with 218 
CONSORT (18), we interpreted this confidence interval in relation to our pre-determined non-219 
inferiority margin (RR=0.81).  To assess superiority, which is also advised in non-inferiority 220 
trials (19), we calculated RRs with 95% confidence intervals. All relative risks (non-inferiority 221 
and superiority) were estimated using marginal standardization via logistic regression (20), 222 
adjusting for nurse. Confidence intervals were calculated via percentile bootstrapping. These 223 
analyses were carried out using the prLogisticBootMarg (prLogistic package) in R.  224 
 225 
Where couples were recruited, we randomised one member and allocated the second non-226 
randomly to the same arm.  As a sensitivity analysis, we re-analysed excluding the second 227 
member of a couple (who was non-randomly assigned).   228 
 229 
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We calculated the proportion of participants attending each of the two post-baseline visits prior 230 
to quit day (visits -1 and 0) and compared these proportions by arm, using a 𝜒2 test with Yates’ 231 
correction for the difference between proportions.  Medication use before quit day was assessed 232 
and reported as percentage using a patch daily, whether short-acting NRT was used and the 233 
number of units of short-acting NRT consumed daily. Both smoking reduction (cigarettes per 234 
day (cpd)) and CO) and medication use were taken from the daily diary and participants without 235 
these data were excluded from the analysis. 236 
 237 
For each participant, mean urge score and withdrawal score were calculated (at baseline, week 238 
+1 and +4) using their responses to the two urge questions and seven withdrawal questions of 239 
the MPSS, respectively. We used a linear generalised estimating equation (xtgee command in 240 
STATA) to explore differences in mean urge and withdrawal symptom scores across these four 241 
weeks, adjusting for nurse and repeated measures. Participants missing scores at all three time-242 
points were excluded from this analysis, but otherwise all participants were included in the 243 
model.  244 
 245 
We assessed the impact on abstinence at four weeks of a participant preferring to quit gradually, 246 
compared with abruptly or no preference. Using logistic regression with the same marginal 247 
standardization as for other abstinence outcomes, we analysed the effect of allocation to 248 
gradual cessation on 4-week abstinence stratified by baseline preference: prefer gradual, prefer 249 
abrupt, no preference. 250 
 251 
Approvals 252 
The study and protocol were authorised by the Nottingham Research Ethics Committee 2 253 
(08/H0408/213), the Medicines & Healthcare products Regulatory Agency, local National 254 
 12 
 
Health Service (NHS) Research & Development offices, and registered before participant 255 
enrolment (ISRCTN22526020).  256 
 257 
Role of funding source 258 
Funding was provided by the British Heart Foundation (PG/08/047/25082). The funder was 259 
not involved in the analysis of the data or the interpretation of the findings, and had no role in 260 
writing the manuscript or submitting it for publication.  261 
 262 
 263 
Results 264 
Recruitment 265 
Of 1097 people enquiring, 697 were randomised (355 to the abrupt arm and 342 to the gradual 266 
arm) by 23 nurses across 31 primary care practices, between June 2009 and December 2011 267 
(Figure 1). 268 
 269 
Baseline characteristics 270 
Participant characteristics were well balanced between trial arms (Table 1).  Participants were 271 
on average 49 years old, equally split between males and females, smoked 20 cigarettes daily, 272 
and had a Fagerstrom Test for Cigarette Dependence (FTCD) score of 6 (21), indicating high 273 
dependence. The majority of participants (94%) described their ethnicity as ‘white’. 274 
 275 
Abstinence rates 276 
The primary outcome, 4-week Russell standard abstinence, was achieved by 39.2% (95% CI: 277 
34.0, 44.4) of the Gradual arm and 49.0% (95%CI: 43.8, 54.2) of the Abrupt arm. Non-278 
inferiority was not demonstrated (unadjusted RR 0.80; 90%CI: 0.68, 0.96).  Rather at 4 279 
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weeks, achieving abstinence was significantly less likely for smokers in the Gradual arm than 280 
those in the Abrupt arm (adjusted RR 0.80, 95%CI 0.66, 0.93). The risk estimates for 281 
secondary outcomes, including six-month prolonged abstinence and point prevalence 282 
abstinence, also indicated superiority of abrupt over gradual cessation (Table 2). Excluding 283 
the second member of a couple gave similar RRs for abstinence at four weeks and six months 284 
(data not shown).   285 
 286 
Visit attendance and adherence 287 
Similar percentages of participants in the two arms attended the week -1 visit; (82% 288 
(n=279/342) of the gradual arm and 85.6% (n=304/355) of the abrupt arm (p=0.147)). 289 
However, significantly fewer participants in the gradual arm attended visit 0, immediately prior 290 
to quit day, (67.0% (n=229/342) versus 83.4% (n=296/355) in the abrupt arm; p<0.001). Fewer 291 
people made a quit attempt (at least 24 hours of self-reported abstinence) in the gradual arm 292 
(61.4%, n=210/342) than the abrupt arm (71%; 252/355); p=0.007. Among participants who 293 
made an attempt, relapse rates were similar in both arms at four week (gradual 36.2% 294 
(n=76/210); abrupt 31.0% (n=78/252); p=0.28) and six month (gradual 74.8% (n=157/210); 295 
abrupt 69.1% (n=174/252); p=0.21) follow-up. 296 
 297 
Participants in the gradual arm cut their cigarette consumption by an average of 48% (target of 298 
50%) after one week (visit -1) (n=264), and by 68% (target of 75%) at visit 0 (n=184). Exhaled 299 
carbon monoxide reduced by 32% at visit -1 (n=275) and by 46% at visit 0 (n=226). There 300 
were also modest reductions in cigarette consumption (n=237, 29%) and carbon monoxide 301 
(n=291, 18%) in the abrupt arm at visit 0 (Figure 2). 302 
 303 
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Medication adherence was generally good. Of those participants who attended visit -1, 81.4% 304 
(n=227/279) in the gradual arm and 89.5% (n=272/304) in the abrupt arm used their nicotine 305 
patch daily in the first week. Of those participants who attended visit 0, 87.3% (n=200/229) in 306 
the gradual arm and 89.2% (n=264/296) in the abrupt arm used their nicotine patch daily in the 307 
second week. Only participants in the gradual arm were provided with short-acting NRT pre-308 
quit. In the first week 76.0% (n=212/279) used it and in the second week 76.0% (n=174/229) 309 
did so.  Of the participants who used short-acting NRT, 84% (n=225/279) chose gum, lozenge, 310 
or sublingual tablets. Although the instruction was to replace each missed cigarette with one 311 
dose of these products, the mean dose was 2.8 (SD=3.1) units per day in the first week (on 312 
average participants reduced their smoking by 11 cigarettes per day), and  4.7 (SD=3.9) units 313 
per day in the second week (average reduction of 15 cigarettes per day). The dose of inhalator 314 
and nasal spray in the remaining participants was similarly low.  315 
 316 
Post-quit urges and withdrawal symptoms  317 
Withdrawal and urge scores were available on at least one assessment for 692 (99.3%) and 695 318 
(99.7%), respectively. Over the whole four weeks there was no evidence of a difference 319 
between arms in withdrawal or urge intensity (withdrawal: p=0.29, urge: p=0.154), both of 320 
which declined over time. At week 4, there were no significant differences between arms in 321 
withdrawal (mean difference: 0.08; 95%CI: -0.03, 0.19) and urge (mean difference: 0.05; 322 
95%CI: -0.06, 0.17) scores. 323 
 324 
Intervention preference 325 
At baseline, 16.9% (n=118) of participants had no preference for which intervention they were 326 
assigned, 32.1% (n=224) would have chosen abrupt quitting and 50.9% (n=355) gradual. 327 
Participants who preferred gradual cessation were significantly less likely to be abstinent at 4 328 
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weeks than those who preferred abrupt cessation (38.3% vs 52.2%; p=0.007).  However, being 329 
allocated to quit abruptly, against their preference, was associated with an increase in 330 
abstinence at 4 weeks (42.0% versus 34.6% who were assigned to gradual cessation), albeit not 331 
significantly (p=0.152). The relative risks of achieving abstinence for the gradual cessation arm 332 
compared with the abrupt arm stratified by baseline preference were: prefer gradual RR=0.82 333 
(95%CI: 0.64, 1.07), no preference 0.80 (95%CI: 0.49, 1.07), and prefer abrupt 0.79 (95%CI: 334 
0.60, 1.08) (Table 3). Of all participants who did not achieve four week abstinence, 61% 335 
(N=112/184) said they would prefer to quit by reduction in a future quit attempt. 336 
 337 
Adverse events 338 
None of the serious adverse events reported during the trial were deemed a reaction to the trial 339 
medication. Three (shoulder arthroscopy; hospitalisation due to salivary gland calculus; 340 
hospitalisation for ovarian cyst) in the gradual cessation arm and one in the abrupt arm 341 
(orchidectomy) occurred whilst participants were using NRT and concurrently smoking. In 342 
participants who adhered to their NRT while still smoking, most symptoms of nicotine 343 
overdose were uncommon, mild and did not differ by arm (Supplement; Table A). Watering 344 
mouth and cold sweats were more common in the gradual than the abrupt arm in both pre-quit 345 
weeks.   346 
 347 
 348 
Discussion 349 
There was clear evidence that quitting abruptly was superior in the short and longer term. 350 
Adherence to behavioural instructions and pre-quit NRT was good, and medication well 351 
tolerated.  People who preferred to quit gradually were less likely to succeed in achieving 352 
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abstinence regardless of how they were allocated to quit; being allocated to quit abruptly, 353 
against their preference, was associated with improved success.   354 
 355 
Potential explanation and comparison of findings 356 
A recent review (9) compared gradual and abrupt cessation approaches and found similar quit 357 
rates, with a summary RR of 0.94 (95%CI: 0.79, 1.13); whereas our data show superior results 358 
with abrupt cessation. We found evidence that gradual cessation was less successful than abrupt 359 
cessation probably because fewer people made a quit attempt when reducing smoking first.  360 
Another similar study reported that gradual cessation seemed to deter people from making quit 361 
attempts and also reported a substantial though not statistically significant advantage of abrupt 362 
cessation over gradual (22).  Population data show that unaided abrupt quit attempts are twice 363 
as successful as quit attempts made by reducing first (5,8). One explanation could be that 364 
gradual cessation requires structure, for example a quit date or reduction goals, to maximise 365 
success (23). People quitting unsupported may not provide this structure for themselves. 366 
Another could be that motivation to quit predicts the means by which people quit, with those 367 
less motivated selecting gradual cessation (24,25), which is supported here by the fact that 368 
those who favoured gradual cessation at baseline were less likely to quit than those who 369 
favoured abrupt quitting, regardless of allocation.  370 
 371 
Strengths  372 
The use of NRT prior to quitting makes reduction more successful (13), but also may enhance 373 
the success of cessation regardess of whether reduction occurs; so we balanced any effect NRT 374 
may have had by offering it to both trial arms.  We also guided participants on how to reduce 375 
their cigarettes using structured plans, which seems to enhance the success of reduction and 376 
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subsequent cessation (23). These two elements combined to ensure that we gave gradual 377 
cessation the best possible chance to succeed.  378 
 379 
Limitations 380 
Blinding was impossible; however there is no reason to believe that false claims of abstinence 381 
would have differed between arms, and the use of biological verification mitigates this further.  382 
Twenty three percent of the English population aged 18 and older are from a minority ethnic 383 
group and most ethnic minority groups have a much lower smoking prevalence than the 384 
majority population(27). Consequently non-white groups formed only 6% of the trial 385 
population and the results may not apply to groups other than white British, although we can 386 
think of no mechanism that might explain effect modification by ethnic group.  387 
 388 
Implications and conclusions 389 
Evidence that gradual is as successful as abrupt cessation would allow smoking cessation 390 
programmes to adopt this method and allow participants to choose, as suggested in guidelines 391 
on tobacco harm reduction from one country (28). These results imply that, in clinical practice, 392 
we should encourage people to stop smoking abruptly and not gradually. However, gradual 393 
cessation programs could still be worthwhile if they increase the number of people that try to 394 
quit or take up support and medication whilst trying. We need population-focused trials to 395 
assess the population impact of promoting and supporting a wider range of quitting options and 396 
programs than most countries currently support (29). However, key future developments will 397 
be finding means to retain smokers in gradual cessation programmes while they reduce, more 398 
successful reduction methods, or aborting reduction before participants deem it a failure and 399 
abandon their quit attempt. For now, however, we conclude that supporting gradual cessation 400 
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may be a useful way to increase cessation in the population, but abrupt quitting is the more 401 
effective method, even in people who have a preference against it. 402 
 403 
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Table 1  Participant baseline characteristics 551 
Characteristic 
All 
(N=697)a 
Gradual cessation  
(N=342)a 
Abrupt cessation 
(N=355)a 
Age, median (IQR) 49.0 (17.0) 49.0 (17.3) 49.0 (17.0) 
Male gender, n/N (%) 350/697 (50.2) 175/342 (51.2) 175/355 (49.3) 
White ethnicity, n/N (%) 648/692 (93.6) 319/341 (93.5) 329/351 (93.7) 
Post-secondary school (15/16 years) educational qualification, 
n/N (%) 
345/678 (50.9) 160/330 (48.5) 185/348 (53.2) 
In paid employment, n/N (%) 382/691 (55.3) 190/340 (55.9) 192/351 (54.7) 
Age started smoking (years), 
median (IQR) 
16.0 (4.0) 16.0 (3.0) 16.0 (4.0) 
Lives with smoker, n/N (%) 266/688 (38.7) 116/335 (34.6) 150/353 (42.5) 
Number of previous quit attempts, median (IQR) 2.0 (2.0) 2.0 (2.0) 2.0 (3.0) 
Type of cigarettes smoked 
-Smokes manufactured cigarettes, n/N (%) 
-Smokes hand-rolled cigarettes, n/N (%) 
-Smokes both manufactured and 
hand-rolled cigarettes, n/N (%) 
 
530/697 (76.0) 
137/697 (19.7) 
30/697 (4.3) 
 
266/342 (77.8) 
61/342 (17.8) 
15/342 (4.4) 
 
264/355 (74.4) 
76/355 (21.4) 
15/355 (4.2) 
Number of cigarettes per day, median (IQR) 20.0 (10.0) 20.0 (10.0) 20.0 (9.0) 
Expired carbon monoxide concentration (ppm), 
median (IQR) 
24.0 (14.0) 24.0 (14.0) 24.0 (14.0) 
Salivary cotinine concentration (ng/ml), median (IQR) 358.5 (212.7) 365.3 (234.5) 349.5 (197.7) 
FTCD score, median (IQR) 6.0 (3.0) 6.0 (3.0) 6.0 (3.0) 
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Preference for abrupt arm, n/N (%) 
Preference for reduction arm, n/N (%) 
No trial arm preference, n/N (%) 
224/697 (32.1) 
355/697 (50.9) 
118/697 (16.9) 
107/342 (31.3) 
179/342 (52.3) 
56/342 (16.4) 
117/355 (33.0) 
176/355 (49.6) 
62/355 (17.5) 
Confidence in quitting, median (IQR)c 4.0 (1.0) 4.0 (1.0) 4.0 (1.0) 
n/N=number of participants; IQR=interquartile range; ppm=parts per million; ng/ml=nanograms per millileter; 552 
FTCD=Fagerstrom Test for Cigarette Dependence 553 
aNumbers of participants used to calculate statistics for each variable vary slightly in some cases due to missing 554 
data (denominators provided); bRange from 0 to 10, where 10=highest level of dependence; cMeasured on a 555 
scale from 1 to 6, where 1=Very low and 6=Extremely high 556 
 557 
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Table 2  Abstinence Outcomes 558 
 559 
 560 
 561 
 562 
 563 
 564 
 565 
 566 
 567 
 568 
 569 
 570 
 571 
 572 
 573 
RS= Russell Standard; N=number of participants; CO=carbon monoxide; CI=confidence interval 574 
aValidated by a carbon monoxide reading of <10 parts per million 575 
bAdjusted for nurse 576 
cNo smoking in the 7 days prior to assessment 577 
 578 
Abstinence outcome Number Abstinent (%) Absolute difference % 
(95%CI) 
Relative Risk 
(95%CI) b 
 
Gradual cessation arm 
(N=342) 
Abrupt  cessation arm 
(N=355) 
Prolonged CO validateda     
      RS abstinence at 4 weeks post-quit 134 (39.2) 174 (49.0) 9.8 (2.5 to 17.1) 0.80 (0.66 to 0.93) 
      RS abstinence at 8 weeks post-quit 100 (29.2) 130 (36.6) 7.4 (0.4 to 14.3) 0.80 (0.63 to 0.95) 
      RS abstinence at 6 months post-quit 53 (15.5) 78 (22.0) 6.5 (0.7 to 12.2) 0.71 (0.46 to 0.91) 
7 day point prevalencec, CO validateda     
        4 week  146 (42.7) 191 (53.8) 9.1 (1.8 to 16.5) 0.83 (0.72 to 0.98)  
        8 week  106 (31.0) 136 (38.3) 7.3 (0.3 to 14.3) 0.81 (0.68 to 1.04)  
       6 month  63 (18.4) 94 (26.5) 8.1 (1.9 to 14.2) 0.70 (0.51 to 0.97) 
Self-reported      
        24 hour  210 (61.4) 252 (71.0) 9.6 (2.6 to 16.5) 0.87 (0.77 to 0.97) 
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 579 
Table 3  Russell standard 4-week quit rates stratified by baseline trial arm preference and trial arm allocation 580 
 581 
 582 
 583 
 584 
 585 
 586 
 587 
 588 
 589 
 590 
 591 
 Trial arm to which participant allocated  
Baseline preference for quitting 
method 
Gradual cessation (N=342) 
n (%) abstinent at 4 weeks 
Abrupt cessation (N=355) 
n (%) abstinent at 4 weeks 
Total (N=697) 
n (%) abstinent at 4 weeks 
Preferred abrupt arm (N=224) 49/107 (45.8%) 68/117 (58.1%) 117/224 (52.2) 
Preferred reduction arm (N=355) 62/179 (34.6%) 74/176 (42.0%) 136/355 (38.3) 
No preference (N=118) 23/56 (41.1%) 32/62 (51.6%) 55/118 (46.6) 
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Figure 1: Participant flow through the Rapid Reduction Trial (RRT) 592 
 593 
Figure 2: Mean (95% CI) pre-quit exhaled carbon monoxide (CO) and cigarettes per 594 
day (cpd) split by trial arm  595 
Figure 2 Legend: Cpd=cigarettes per day; CO=carbon monoxide; ppm=parts per million 596 
Gradual cpd Ns (baseline n=342; visit -1 n=264; visit 0 n=184). Gradual CO Ns (baseline 597 
n=342; visit -1 n=275; visit 0 n=226). Abrupt cpd Ns (baseline n=355; visit -1 n=299; visit 0 598 
n=237). Abrupt CO Ns (baseline n=354; visit -1 n=299; visit 0 n=292).  599 
  600 
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Figure 1. 601 
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Figure 2. 605 
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